What Can hiPSC-Cardiomyocytes Teach Us about Modeling Complex Human Disease Phenotypes?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27588742.
- Also identified by DOI 10.1016/j.stem.2016.08.016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Using induced pluripotent stem cell-derived cardiomyocytes to predict patient-specific responses to drug treatments requires that they maintain inter-individual variability for RNA expression and recapitulate phenotypic responses in vitro. In this issue of Cell Stem Cell, Matsa et al. (2016) show that expression differences between hiPSC-cardiomyocytes provide a personalized drug testing platform to evaluate potential efficacy and cardiotoxicity.
Medical subject headings
- Induced Pluripotent Stem Cells
- Myocytes, Cardiac